Healthcare

Revenue increased from AUD 12.267 billion in FY25 to AUD 13.487 billion in FY26, a rise of 9.9%. Underlying EBITDA increased from AUD 585 million to AUD 614 million, representing 5.0% growth.

MSB reported RYONCIL net revenue of USD 115 million for FY26, including USD 36 million during the June quarter. The product was the principal contributor to total reported FY26 revenue of approximately USD 120.3 million, substantially above the USD 17.2 million recorded in the …

NEU recorded H1 2026 revenue of AUD 42.746 million, compared with AUD 39.723 million in the corresponding period, representing 8% growth. Royalty income earned from the commercial medicine DAYBUE reached USD 23.3 million, or AUD 33.2 million. The royalty figure increased 29% in U.S. …

During Q3 2026, PYC advanced its PYC-003 program for polycystic kidney disease through a combined Phase 1a and Phase 1b trial. Following a safety review, dosing progressed to the 2.4 mg/kg cohort in the multiple-ascending-dose portion of the study. The assessment followed earlier single-dose …

FY26 operating revenue was AUD 7.1 million, representing 21% growth compared with FY25. The company reported margins above 90% on its operating revenue measure. Software products were in use at 540 sites worldwide as at 30 June 2026, an increase of 39% over the …

FY26 revenue increased to AUD 203.9 million from AUD 198.6 million in FY25, a 3% reported increase. The company stated that revenue would have reached AUD 211.5 million on a constant-currency basis, corresponding to 6% growth. The alternate measure removes movements in exchange rates …

FY26 revenue rose 25.6% to AUD 788.7 million. Operating EBITDA increased 30.3% to AUD 164.8 million, while the operating EBITDA margin expanded by 80 basis points to 20.9%. The company attributed the performance to a combination of patient activity,Businessintegration benefits andOperating Leverageacross its larger …